A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma

Protocol
13-073
Full Title
A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Phase
I
Purpose

The purpose of this study is to find the highest dose of an investigational drug called IMGN529 that can be given safely in patients with B-cell non-Hodgkin lymphoma (NHL) that has returned or continued to grow despite standard therapy.

IMGN529 is composed of two parts: an antibody that binds to a protein on lymphoma cells called CD37, and a chemotherapy drug called DM1 which is transported by the antibody and causes cancer cells to die. IMGN529 is given intravenously (by vein).

Co-Investigators

Zelenetz, Andrew, MD, PhD

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have NHL that has returned or continued to grow despite standard therapy that included rituximab.
  • Patients with T-cell lymphoma may not participate.
  • There is no limit on the number of prior treatments, but patients should have recovered from the serious side effects of therapy before entering the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. M. Lia Palomba at 212-639-7186.

Disease(s)
Lymphoma: Non-Hodgkin's Lymphoma
Locations
Related Diseases